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tumours
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Paediatric adrenocortical carcinoma is a rare malignancy with poor prognosis. Here
we analyse 37 adrenocortical tumours (ACTs) by whole-genome, whole-exome and/or
transcriptome sequencing. Most cases (91%) show loss of heterozygosity (LOH)
of chromosome 11p, with uniform selection against the maternal chromosome. IGF2 on
chromosome 11p is overexpressed in 100% of the tumours. TP53 mutations and chromosome
17 LOH with selection against wild-type TP53 are observed in 28 ACTs (76%). Chromosomes
11p and 17 undergo copy-neutral LOH early during tumorigenesis, suggesting tumour-driver
events. Additional genetic alterations include recurrent somatic mutations in ATRX and
CTNNB1 and integration of human herpesvirus-6 in chromosome 11p. A dismal outcome is
predicted by concomitant TP53 and ATRX mutations and associated genomic abnormalities,
including massive structural variations and frequent background mutations. Collectively,
these ﬁndings demonstrate the nature, timing and potential prognostic signiﬁcance of
key genetic alterations in paediatric ACT and outline a hypothetical model of paediatric
adrenocortical tumorigenesis.
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A
drenocortical tumours (ACTs) are rare1. A good outcome,
as with most paediatric embryonal tumours, requires early
diagnosis and complete surgical resection. Children with
locally advanced or metastatic disease have a very poor prognosis,
even with surgery and intensive chemotherapy2.
Childhood ACT is often associated with germline TP53
mutations (Li-Fraumeni syndrome)3 or constitutional genetic
and/or epigenetic alterations affecting chromosome 11p15
(Beckwith-Wiedemann syndrome, BWS)4. Both Li-Fraumeni
syndrome and BWS have highly variable phenotypes, which
include susceptibility to ACT and other embryonal malignancies5.
The factors contributing to sporadic paediatric ACTs are
unknown, although the similarity of these cases to those with a
constitutional predisposition suggests a common mechanism of
tumorigenesis1.
ACT is uniquely amenable to molecular studies relevant to
paediatric embryonal neoplasms in general. First, the marked
clinical endocrine manifestations of ACT (for example, viriliza-
tion and Cushing syndrome) allow access to tumour tissue at an
early disease stage. Second, ACT shares the epidemiological and
molecular features of embryonal tumours5. Finally, a cluster of
ACTs arising from a founder TP53 mutation (R337H) in
southern Brazil allows biologic, prognostic and therapeutic
studies in a relatively large group of cases with a common
predisposing factor6–9.
Staging of paediatric ACT is based on tumour size and
evidence of residual tumour after surgery1. Histopathologic
classiﬁcation criteria, which have been invaluable in
distinguishing adenoma (benign) from carcinoma (malignant)
in adult ACTs10, have a limited role in guiding therapeutic
decisions in paediatric ACTs, the great majority of which
are classiﬁed as carcinomas or histology of undetermined
malignant potential11,12. To advance our understanding of the
initiation and progression of paediatric ACT, we undertook a
comprehensive genomic analysis of 37 representative cases,
including 12 tumours associated with the germline TP53-
R337H mutation, using a combination of whole-genome
sequencing (WGS), whole-exome sequencing (WES) and
transcriptome proﬁling (RNA-seq).
Results
Clinical data. The clinical and biological characteristics of the 37
newly diagnosed ACT cases studied by WGS and WES are
summarized in Supplementary Table 1a,b. The median age of the
25 girls and 12 boys at diagnosis was 53.5 months (range, 9.7–
184.7 months). Tumours were sporadic (n¼ 10) or associated
with constitutional cancer predisposition conditions (Brazilian
founder TP53-R337H (n¼ 12); other types of germline TP53
mutations (n¼ 13) and BWS (n¼ 2)) and included 29 carcino-
mas, 3 adenomas and 5 tumours of undetermined malignant
potential. These cases were selected on the basis of availability of
paired tumor and germline samples and isolation of high-quality
tumour DNA. Although treatment was not uniform, it generally
adhered to the Children’s Oncology Group (COG) ARAR0332
protocol1, consisting of surgery alone for stage I and II disease,
and surgery followed by intensive chemotherapy (cisplatin,
doxorubicin, etoposide and mitotane) for advanced-stage (III
and IV) disease. At a median follow-up of 38 months, 11 of 35
(31%) patients had experienced an adverse event (relapse or
death). Five of these eleven had died of progressive disease
at the time of this report, and six remained alive in second
complete remission. Two patients were lost to follow-up.
Clinical data from 34 additional ACT patients studied as an
independent comparison group (‘convenience cohort’) is included
in Supplementary Table 1c.
Genome and transcriptome analyses. Primary ACTs and mat-
ched peripheral blood DNA were analysed by WGS (n¼ 19) at an
average 41.9X coverage (Supplementary Table 2a) or by WES
(n¼ 18) at an average 84.8X coverage (Supplementary Table 2b;
Pediatric Cancer Genome Project, http://pcgpexplore.org/). All
genetic lesions, including single-nucleotide variations (SNV),
small insertions/deletions (indels) and structural variations (SVs),
were experimentally validated (Supplementary Fig. 1). In the
WGS samples, the median number of nonsilent point mutations
was 5 (range, 1–97), the median background mutation rate
(BMR) was 3.78 10 7 (range, 5.01 10 8–2.40 10 6) and
the median number of SVs per case was 61 (range, 0–812;
Supplementary Table 3a–d). Transcriptome proﬁles of normal
adrenocortical tissue (n¼ 6) and ACT samples from the WGS
cohort (n¼ 16) were analysed using RNA sequencing (RNA-seq;
Supplementary Table 2c).
TP53 mutations. Germline TP53 mutations were present in 25 of
the 37 patients (68%) in the combined WGS and WES cohorts, 12
of which were the Brazilian founder R337H mutation (Fig. 1a and
Supplementary Fig. 3a). Somatic mutations (R175H, R273C and a
homozygous deletion of B200 kb of chromosome 17 encom-
passing TP53) were also identiﬁed in 3 of the 12 ACTs associated
with wild-type germline TP53 (Supplementary Fig. 3a,b).
Sanger sequencing identiﬁed germline TP53 mutations in 11 of
the 34 cases (32%) in the independent comparison cohort
(Supplementary Table 1c). Of the 23 ACTs in this group
associated with germline wild-type TP53, three tumours acquired
a TP53 mutation (c.134_135 insT, E180K and R273H;
Supplementary Fig. 4a).
Somatic ATRX mutations. ATRX encodes a helicase that func-
tions in chromatin remodelling and telomere structural main-
tenance, and it cooperates with DAXX to incorporate the histone
variant H3.3 into chromatin13. ATRX somatic nonsense
mutations and SVs deleting multiple exons were identiﬁed by
WGS in 6 of the 19 ACTs (32%), all of which were associated with
germline TP53 mutations (Fig. 1a and 2a,b). An ATRX somatic
missense mutation (R2164S) was also identiﬁed by WES in the
case with somatic homozygous deletion of TP53 (Fig. 2a and
Supplementary Fig. 3b). No mutations were detected in the
coding region of DAXX or TERT by WGS or WES. Furthermore,
no mutations were identiﬁed in the TERT core promoter by
targeted Sanger sequencing. Although broad regional
ampliﬁcation encompassing the TERT locus was observed in 13
of the 19 WGS cases (68%), no TERT expression was detected
with RNA-seq.
WGS-based telomere length analysis showed an increase in
telomeric DNA in all six tumours with ATRX mutations, but not
in tumours with wild-type ATRX (P¼ 3.7 10 5, Fisher’s exact
test; Fig. 2c). Telomere ﬂuorescence in situ hybridization (FISH)
analysis of 22 available formalin-ﬁxed, parafﬁn-embedded
tumour specimens revealed large, ultrabright telomere foci
(Fig. 2d) in cases harbouring ATRX mutations (n¼ 5), suggesting
the activation of an alternative lengthening of telomere mechan-
ism. Telomere foci were also observed in the SJACT023 tumour,
although WES did not detect an ATRX mutation.
Somatic b-catenin mutations. Somatic b-catenin (CTNNB1)
mutations were identiﬁed in 3 of the 37 (8%) tumours analysed in
the combined WGS and WES cohorts (Fig. 1a and Supplementary
Fig. 5). Targeted Sanger sequencing of CTNNB1 exon 3 revealed
10 additional somatic mutations in 34 paediatric ACTs in the
independent comparison cohort (Supplementary Fig. 4b). Over-
all, CTNNB1 mutations (n¼ 13) were detected only in tumours
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with wild-type germline TP53 (n¼ 35) and not in those with
constitutional TP53 mutations (n¼ 36; P¼ 2.5 10 5, Fisher’s
exact test). However, three tumours with somatic CTNNB1
mutations had also acquired a TP53 mutation (IPACTR001,
IPACTR013 and IPACTR019; Supplementary Fig. 4b and
Supplementary Table 1c).
Genomic classiﬁcation of ACT. WGS deﬁned three groups of
paediatric ACT based on the mutational status of TP53 and
ATRX: Group 1 germline TP53 and somatic ATRX mutations
(n¼ 6); Group 2 germline TP53 mutations and no ATRX muta-
tion (n¼ 9); and Group 3 both wild-type TP53 and ATRX (n¼ 4;
Fig. 1a). Group 1 cases had signiﬁcantly greater tumour weight
(P¼ 0.007, Mann–Whitney test), were signiﬁcantly more likely to
have stage 3 or 4 disease (P¼ 0.020, Kendall test) and had poorer
event-free survival than Groups 2 and 3 (P¼ 5.0 10 5, exact
log-rank test; Fig. 1a,b). Group 1 ACTs also had a signiﬁcantly
larger number of SVs (P¼ 0.021, Mann–Whitney test) and higher
BMR (P¼ 0.015, Mann–Whitney test; Supplementary Fig. 3c). In
addition, these tumours showed signiﬁcantly higher expression of
genes associated with chromosome instability and deregulation of
cell cycle control (PTTG1, P¼ 0.019; ESPL1, P¼ 0.015; CCNB1,
P¼ 0.018; BUB1, P¼ 0.023; TPX2, P¼ 0.032; and MCM2,
P¼ 0.040, t-test; Fig. 1a). Although all cases in Group 2 carried
germline TP53 mutations (eight of nine cases had the founder
R337H mutation and were diagnosed in southern Brazil), they
displayed variable clinical ﬁndings. Group 2 patients with the
R337H mutation were young (median age, 30 months), exhibited
signs of virilization and had relatively small tumours (median
tumour weight 68 versus 585 g in Group 1 (Po0.006, Wilcoxon
rank sum test)). These tumours showed variable numbers of SVs
and BMR, and variable expression of selected target genes (Fig. 1
and Supplementary Fig. 3c). A distinguishing feature of this
group is the lack of ATRX mutations and the shortening of tel-
omeres as compared with Group 1. Group 3 tumours showed a
relatively small number of SVs and a low BMR, and gene
expression of those selected genes was similar to that in normal
adrenocortical tissue, consistent with their more favourable out-
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Figure 1 | Association between molecular and clinicopathological features of paediatric adrenocortical tumours. (a) Upper panel: clinicopathological
features of 19 patients in the WGS cohort. Centre panel: genetic alterations, including mutational status of TP53 (R337H identiﬁed by asterisk), ATRX and
CTNNB1; telomere length; number of SVs; BMR; chromothripsis and kataegis. Und: undetermined malignancy. Lower panel: RNA expression of selected
genes involved in chromosomal segregation and cell cycle control. Three distinct tumour groups (labelled below) emerged from this analysis. Control:
normal adrenocortical tissue. (b) Kaplan–Meier probability of event-free survival (exact log-rank test) of paediatric ACT patients in group 1 versus others.
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WGS did not reveal any speciﬁc genetic alterations that
distinguished ACTs harbouring the founder TP53-R337H from
tumours with other TP53 mutations. However, R337H tumours
that had acquired an ATRX mutation (cases SJACT062 and
SJACT069) clustered in Group 1 and exhibited an aggressive
phenotype (Figs 1 and 3). The remaining eight R337H cases
showed variable molecular proﬁles and disease stage (Fig. 1 and
Supplementary Fig. 2). Figure 3 illustrates the relationship among
histopathological features, tumour weight, stage and complexity
of genomic abnormalities for four cases with the same
predisposing TP53-R337H germline mutation.
Loss of heterozygosity of chromosomes 11 and 17. Chromosome
17 loss of heterozygosity (LOH) was observed in 28 of the 37 ACTs
(76%) by WGS and WES. All tumours with germline (n¼ 25) and
somatic (n¼ 3) TP53 mutations underwent LOH with selection
against the wild-type allele (Supplementary Fig. 2). More speciﬁcally,
WGS demonstrated copy-neutral LOH (cn-LOH) of the entire
chromosome 17 in all tumours associated with germline TP53
mutations (n¼ 15), as well as in two (SJACT003 and SJATC004) of
the four cases with wild-type TP53 (Supplementary Fig. 2).
Chromosome 11p LOH was also identiﬁed in 32 of the 35
ACTs (91%). Two BWS patients (SJACT009 and SJACT065)
with germline 11p homozygosity, indicative of uniparental
disomy, were excluded from the analysis as LOH could not be
assessed (Supplementary Fig. 2 and Fig. 4a). Furthermore,
cn-LOH of chromosome 11p was demonstrated by WGS in 14
of the 18 informative ACTs (Supplementary Fig. 2). Microsatellite
marker analysis of an additional 22 paediatric ACT cases
from our independent comparison cohort revealed chromosome
11p LOH in 20 tumours (95%, as IPACTR004 was excluded
due to uniparental disomy; Supplementary Fig. 4c). Remarkably,
100% of the cases from the combined cohorts that
underwent chromosome 11p15 LOH and had available parental
DNA (n¼ 23) selectively retained the paternal chromo-
some (P¼ 2.4 10 7, sign test; Fig. 4a and Supplementary
Fig. 4c).
Human chromosome 11p15 contains a large cluster of
imprinted genes, including IGF2, CDKN1C, KCNQ1 and H19.
IGF2 is a paternally expressed fetal growth factor, whereas the cell
cycle inhibitor CDKN1C (p57), potassium channel protein
KCNQ1 and the noncoding H19 transcripts are expressed from
the maternal allele. Expression of genes localized at 11p15
0
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Figure 2 | Somatic ATRXmutations and telomere analysis of paediatric adrenocortical tumours. (a) Distribution of nonsilent single-nucleotide variations
in ATRX (blue dots: nonsense mutations; red dot: missense mutation). (b) Wiggle plots showing internal deletion of multiple exons in the ATRX gene in
SJACT005, SJACT062 and SJACT069 (diagnostic tumour [D] and germline [G] samples). (c) Relative telomere length determined by WGS in paediatric
ACTs versus matched germline samples. (d) Images of tumour samples hybridized with the telomeric FISH (red) and chromosome 4p (green) probes and
stained with DAPI to visualize the nucleus (blue). High-magniﬁcation views show the large, ultrabright signal in ATRX-mutant adrenocortical tumour cells
(SJACT007). Scale bars, 1mm.
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(chr11:1704500–3658789) was analysed with transcriptome
proﬁling. RNA-seq conﬁrmed greater expression of IGF2 in all
tumours in the WGS cohort compared with normal adrenocor-
tical tissue (P¼ 2.987 10 7, t-test; Supplementary Fig. 6).
Expression of KCNQ1, CDKN1C and H19 was low in most cases,
consistent with loss of the maternal chromosome 11p. SJACT006,
which retained both parental copies of chromosome 11, also
displayed elevated IGF2 expression and deregulation of mater-
nally expressed genes, suggesting a loss of imprinting control at
this locus (Supplementary Fig. 6).
Timing of cn-LOH of chromosomes 11 and 17. To infer the
temporal order of somatic SNV acquisition and cn-LOH in
chromosomes 11 and 17, we compared the mutant allele fractions
(MAFs) of SNVs in cn-LOH regions to allelic imbalance (AI)
values, which express the different MAFs (germline hetero-
zygous single-nucleotide polymorphisms (SNPs)) in tumour
versus germline samples (Fig. 4b,c and Supplementary Fig. 7).
A cn-LOH event in the tumour cells will lead to an expected
AI value of 0.5. Similarly, somatic SNVs acquired before
cn-LOH would result in either a homozygous reference allele (R)
or a homozygous mutant (M) allele, while SNVs accumulated
after cn-LOH would remain heterozygous in the absence of
a second hit (Supplementary Fig. 7a). Our analysis of 14
informative WGS samples demonstrated that most SNVs in
chromosomes 11p and 17p were acquired after cn-LOH, although
SJACT005 underwent cn-LOH during SNV accumulation
(Fig. 4b,c and Supplementary Fig. 7b). These ﬁndings indicate
that cn-LOH of chromosomes 11p and 17p occurs early in
adrenocortical tumorigenesis and precedes the accumulation
of SNVs in these regions.
Chromosomal integration of human herpesvirus-6. Human
herpesvirus-6 (HHV6) was detected by WGS in the germline and
tumour DNA of SJACT004 (Fig. 5a) and by Sanger sequencing in
SJACT017. FISH analysis conﬁrmed the site of chromosomal
integration of HHV6 as the telomeric region of 11p in both cases
(Fig. 5b). PCR analysis demonstrated paternal transmission
of chromosomally integrated HHV6 in SJACT017 (Fig. 5c).
Microsatellite marker analysis and WGS conﬁrmed chromosome
11 LOH with retention of integrated HHV6 in both cases
(Supplementary Figs 2 and 4c and Fig. 4a). Genomic and tran-
scriptome analyses of SJACT004 identiﬁed few somatic SNVs and
SVs, but showed elevated IGF2 expression (Supplementary Figs 2
and 6). Both ACTs were small, stage 1 tumours and with good
prognosis (Supplementary Table 1a,b).
Other genetic events. Chromosomal copy number alterations
(CNAs) were also assessed by a modiﬁed version of GISTIC
(genomic identiﬁcation of signiﬁcant targets in cancer). Deletion
of chromosome 4q34 was observed in 11 of the 19 tumours
(58%; Supplementary Fig. 8a,b). The most commonly deleted
region overlapped a 5-Mb area encompassing LINC00290
(long intergenic nonprotein-coding RNA 290)14.
Chromosomal copy number gains were widespread, with 9q
being over-represented and ampliﬁed in 16 of the 19 WGS
ACTs, similar to previously reported ﬁndings (Supplementary
Fig. 8a,c)14. Chromosome shattering consistent with
chromothripsis15 (Supplementary Fig. 9) and patterns of
localized hypermutation (kataegis16; Supplementary Fig. 10)
were observed in late-stage tumours (Fig. 1a). Structural
variants resulting in the expression of fusion genes were



























































































































































































































































































































Figure 3 | Histopathological and genomic features of TP53-R337H-associated ACTs. All tumours had a high mitotic rate (45 per 50 high-power ﬁelds,
H&E, 400). Histology showed a vague nested and trabecular pattern with occasional unpatterned cellular sheets of variable size. Three cases
(SJACT063, SJACT062 and SJACT069) had a high nuclear grade and marked cellular pleomorphism. SJACT070 showed occasional enlarged
hyperchromatic nuclei with one or more prominent nucleoli. Necrotic cells and atypical mitotic ﬁgures (arrow) are identiﬁed in SJACT63 and SJACT69.
Accumulation of genomic alterations illustrated by the Circos plots (bottom panels) paralleled an increase in tumour weight and correlated with a more
aggressive tumour phenotype (Group 1 versus Group 2). Note: labels for gene-disrupting SVs (SJACT063 and SJACT062) and noncoding mutations
(SJACT069) were removed from the Circos plots.
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Discussion
Our genomic ﬁndings deﬁne cn-LOH of chromosome 11p, with
selection against the maternal chromosome and consequent IGF2
overexpression, as an early event and a hallmark of paediatric
adrenocortical tumorigenesis.
Although paediatric ACT is strongly associated with germline
TP53mutations17–19 (60–70% of children with ACT3), only 4–6%
of carriers develop ACTs1, suggesting the involvement of
cooperating genetic alterations. We propose that germline TP53
mutations may contribute to adrenocortical tumorigenesis by
promoting chromosomal instability20,21. In this setting, aneuploid
adrenocortical cells that experience chromosome 11p LOH and
deregulation of imprinted genes on 11p15 may be selected and
expanded via constitutive overexpression of IGF2, which encodes
a potent mitogen and fetal growth-promoting protein22,23. This
mechanism is consistent with chromosome 11p abnormalities
and IGF2 overexpression in all cases of ACT with germline TP53
mutations. Clones that undergo chromosome 17 LOH and lose
wild-type TP53 become more unstable, accumulate additional
SNVs and are selected for further expansion. In support of this
hypothesis, our temporal studies place cn-LOH of chromosomes
11p and 17 during early tumorigenesis, before the acquisition of
widespread genomic alterations.
Our WGS study included 10 Brazilian cases with the founder
TP53-R337H mutation, which could inﬂuence the resulting
genomic landscape ﬁndings. TP53-R337H is a missense mutation
that is partially functional6,24; hence, we expected that genomic
changes could be different from those with nonfunctional
mutations. Our genomic studies showed that some cases with
the R337H mutation had secondary genetic events that were
similar to those seen with other types of TP53 mutations, such as
concomitant cn-LOH of chromosomes 11 and 17p early during
tumorigenesis, as well as the deregulation of IGF2 expression and
acquired ATRX mutations. These ﬁndings are consistent with
those from high-density SNP analysis that demonstrated that the
pattern of gains and losses is similar in paediatric ACTs with
R337H and other TP53 mutations14. However, other cases with
R337H mutations had much simpler genomes similar to those
with wild-type TP53. It is possible that secondary genomic
changes increase with time from tumour initiation to diagnosis.
Alternatively, other genetic constitutional or acquired changes
account for the observed heterogeneity observed in cases with the
R337H mutations. Further studies will be required to examine
these possibilities.
LOH of chromosome 11p15 and genomic imprinting abnorm-
alities within this region that lead to constitutive IGF2 expression
are features of many other paediatric tumours, including
rhabdomyosarcoma25, Wilms tumour26 and hepatoblastoma27.
Similarly, adult adrenocortical carcinomas, but not adenomas,
show genomic imprinting abnormalities at chromosome 11p15
(refs 28,29). However, transgenic mouse models demonstrate that
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Figure 4 | Characterization and timing of chromosome 11 and 17 LOH in paediatric ACT. (a) Microsatellite analysis of chromosome 11p15 in the WES
cohort. All cases with available parental DNA demonstrated selective loss of maternal chromosome 11p15 (n¼ 8, purple). (b) Temporal order of
chromosome 11p and 17p cn-LOH and accumulation of SNVs in SJACT002. Scatter plots show MAFs of somatic SNVs and their genomic positions
(individual dots) combined with two-dimensional (2D) density plots of AI values of germline heterozygous SNPs in cn-LOH regions of chromosomes 11p
(left) and 17p (centre). At right, AI values in cn-LOH regions of chromosomes 11p and 17p were compared with the MAF distribution of somatic SNVs in
genome-wide cn-LOH regions. (c) A three-dimensional (3D) scatter plot summarizes the temporal order of cn-LOH of chromosomes 11p and 17p and
somatic SNV accumulation in paediatric ACTs. Shown are the median AI values for the chromosome 11p cn-LOH region, the median AI values for the
chromosome 17p cn-LOH region and the median MAF of SNVs in genome-wide cn-LOH regions of 14 cases; SJACT002 and SJACT005 are labelled. See
also Supplementary Fig. 7b.
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adrenocortical tumorigenesis30 but must cooperate with other
genetic alterations, such as activation of b-catenin31. Consistent
with these ﬁndings, CTNNB1-activating mutations were relatively
frequent in our cohort, particularly in cases with germline wild-
type TP53.
Assie´ et al.29 recently reported the characterization of 45 adult
adrenocortical carcinomas (ACCs) using an integrated genomic
analysis approach. A comparison of our ﬁndings to this published
study highlights similarities and differences in the genetic changes
that occur in paediatric and adult ACTs (Supplementary Table 5).
Remarkably, 11p15 LOH involving the IGF2 locus was observed
in both paediatric ACT (91%) and adult ACC (82%),
underscoring the critical role of deregulated IGF2 expression in
adrenal cortex tumorigenesis. Aneuploidy with widespread
chromosomal gains (for example, chromosome 19) and
deletions (for example, 4q34.3) was also observed in both
paediatric and adult cases. However, ampliﬁcation of
chromosome 9q, a region that includes NOTCH1 and NR5A1
(Steroidogenic Factor-1), occurred in 90% of paediatric ACTs
(Supplementary Fig. 8a,c), but not in adult ACC29. Activating
mutations in CTNNB1 were common to both paediatric and adult
ACT, but additional mutations within the Wnt/b-catenin
signalling pathway, in particular ZNRF3, were only observed in
adult tumours. Germline TP53 mutations were predominantly
associated with paediatric ACT, whereas somatic TP53 mutations
were relatively infrequent in both groups. The alternative
lengthening of telomere phenotype was associated with DAXX
or ATRX mutations in adult tumours, but exclusively with ATRX
mutations in paediatric cases. Ampliﬁcation of TERT was
common in both groups, but no TERT mutations were detected
in the paediatric cases, consistent with the absence of TERT
expression.
A lack of strong prognostic indicators has limited progress in
the management of childhood ACT. Overall event-free survival is
only B50%, and patients with advanced-stage disease have very
poor overall survival1,2. Unlike studies of other paediatric
embryonal tumours32–34, histopathological examination11 and
molecular ﬁndings35 in paediatric ACT has not produced relevant
prognostic categories or novel treatment approaches. Tumour
weight, volume and surgical resectability form the basis of the
current COG disease-stage classiﬁcation1. However, this system
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Figure 5 | Chromosomal integration of human herpesvirus-6 in paediatric ACT. (a) Coverage plot for cases SJACT004 and SJACT005 showing
diagnostic tumour (D) and germline (G) samples reveals integration of the full-length HHV6 genome in SJACT004. The HHV6 genome is duplicated in the
tumour sample as a consequence of cn-LOH. (b) FISH of metaphase chromosomes from peripheral blood conﬁrmed HHV6 integration at 11p in both cases.
The MLL probe (chromosome 11q23) was used as control (left, SJACT004; right, SJACT017). (c) HHV6 MCP (major capsid protein) and U94 were
ampliﬁed with PCR from SJACT017 (germline and tumour) and parental DNA demonstrating paternal vertical transmission of integrated HHV6. Exon 6 of
the TP53 gene was ampliﬁed as DNA quality control.
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small, completely excised tumours, while others are cured despite
histological ﬁndings suggestive of carcinoma36.
Our genomic analysis opens opportunities to improve the
current tumour size-histology-disease stage prognostic scheme for
paediatric ACT1,2. Notably, tumours with both germline TP53 and
somatic ATRX mutations (Group 1) were signiﬁcantly associated
with high tumour weight, advanced disease (COG stage III/IV)
and poor event-free survival. SJACT069 (R337H) exempliﬁes such
a case; it was staged as limited disease (COG stage II) and initially
managed with surgery alone, but later metastasized to the lungs.
Moreover, ﬁve of six patients in Group 1 had adverse events
(relapse or death), consistent with the genomic ﬁndings indicative
of an aggressive phenotype. Cases with germline TP53 mutations
and wild-type ATRX (Group 2) are clinically and molecularly
heterogeneous. Although all cases in this group carried TP53
mutations (eight of the nine cases harbour the founder R337H),
they had fewer genomic abnormalities, smaller tumours and
generally much better clinical outcome than cases in Group 1. It is
not surprising that patients in southern Brazil with the R337H
mutation were diagnosed earlier, as paediatricians of that region
are familiar with the ﬁrst signs of ACT and promptly refer these
children for treatment. However, three patients (one with the
TP53 G245C and two with the Brazilian R337H mutation)
overexpressed genes associated with chromosome instability and
cell cycle control (Fig. 1a; Supplementary Table 1). The two cases
with R337H required chemotherapy because of advanced-stage
disease in one and tumour rupture in the other. The patient with
the G245C, a child more than 10 years of age at diagnosis of ACT,
had delayed diagnosis of a very large tumour in the absence of
endocrine signs (a ‘nonfunctional’ tumour). This child was treated
with surgery followed by chemotherapy, but eventually died of
relapsed disease. These observations suggest that paediatric TP53-
associated tumours arise from a simpler genomic background
(adenoma or undetermined malignant potential) and progress to
acquire complex and unstable genomic aberrations (carcinoma).
The results of newborn screening for the TP53 mutation in Brazil
and surveillance of carriers for early signs of ACT9 are consistent
with this concept37. Finally, ACTs with wild-type TP53 exhibit
relatively simple genomes and, despite their large size in some
cases, patients generally have a good outcome. Because of the
small number of these cases, additional genomic studies will be
needed to clarify the role of molecular changes in this subset of
patients.
In two of our cases (SJACT004 and SJACT017), HHV6 was
selectively integrated into the telomeric region of chromosome
11p. HHV6 is known to integrate into the genome at a low
frequency (B1%), preferring the telomeric regions of chromo-
somes 9q, 11p, 17p and 19q (refs 38,39). A recent report
documented the role of integrated HHV6 in disrupting telomeres,
leading to selective aneuploidy40. Whether chromosomal
integration of HHV6 facilitates 11p cn-LOH and deregulation
of imprinting at the 11p15 locus, leading to IGF2 overexpression,
remains to be determined.
In summary, our study identiﬁed key genetic alterations and
their temporal relationships in paediatric adrenocortical tumor-
igenesis. The genomic complexity of childhood ACTs, particu-
larly those with both germline TP53 and acquired ATRX
mutations, may explain the failure of standard chemotherapy,
underscoring the importance of early diagnosis and improved
prognostic classiﬁcation.
Methods
Patients and samples. Written informed consent was obtained from parents or
legal guardians for inclusion in the St Jude Children’s Research Hospital (St Jude)
International Pediatric Adrenocortical Tumor Registry (IPACTR; http://clinical-
trials.gov/show/NCT00700414) or for participation in COG ARAR0332 protocol
(http://clinicaltrials.gov/show/NCT00304070). IPACTR registers childhood cases
of ACT worldwide. COG studies enroll patients from the United States, Canada
and southern Brazil, where 90% of cases carry the founder TP53-R337H mutation.
Diagnosis was made on the basis of the gross and histologic appearance of tissue
obtained at surgery. The diagnosis of ACT was centrally reviewed and conﬁrmed.
Tumours were further classiﬁed as adenoma (benign), carcinoma (malignant) or
having histology of undetermined malignant potential. No attempt was made to
obtain individual tumour scores.
Samples for WGS (n¼ 19) and WES (n¼ 18) included matched peripheral
blood and primary tumour tissue from 26 IPACTR patients and 11 COG patients.
An additional group of 34 IPACTR patients with matched primary tumour and
blood samples, and blood-derived DNA from 23 sets of parents, were included for
analysis of chromosome 11p LOH, TP53 and CTNNB1 mutation. Six samples of
normal adrenocortical tissue obtained during nephrectomy for Wilms tumour were
used as controls in gene expression studies as well 16 tumour samples studied in
the WGS cohort. All tumour samples underwent estimation of the purity-adjusted
MAF, tumour purity and tumour heterogeneity and quantitative analysis of
chromothripsis41. This study was approved by the St Jude Institutional Review
Board and by the Cancer Therapy Evaluation Program of the National Cancer
Institute (ARAR12B1).
Tumour purity estimations. For germline heterogeneous SNPs, LOH measures
the absolute difference between the MAF in tumour and that in germline sample
(0.5). LOH is the result of copy number alterations and/or cn-LOH in tumour cells.
Compared with copy number gains (a single copy gain in 100% tumour results in a
LOH value of 0.167), regions with copy number loss showed stronger LOH (a
single copy loss in 100% tumour result in a LOH value of 0.5). Consequently, we
used LOH signals in copy neutral or heterozygous copy number loss regions (CNA
value between [ 1, 0]) to estimate tumour purity for all WGS samples. Brieﬂy,
a single copy loss in x% tumour cells resulted in an estimated CNA value of
 x100 and a LOH value of x400 2x. Assuming that the remaining LOH signal came
from cn-LOH (cn-LOH in x% tumour cell resulted in a LOH value of x200), the
tumour content in a region could be estimated as the sum of the fraction with copy
number loss and the fraction with cn-LOH by: CNAþ 2  ðLOH CNA4þ 2CNAÞ.
Using tumour content estimates from various regions within the genome, we
performed an unsupervised clustering analysis using the mclust package (version
3.4.8) in R (version 2.11.1). The tumour purity of the sample was deﬁned as the
highest cluster centre value among all clusters.
Purity-adjusted MAF estimation. MAF for validated SNVs was estimated as
No: of mutant reads
ðNo: of total readsÞðtumour purityÞ using deep sequencing data.
Tumour heterogeneity estimation. We used all validated autosomal SNVs
satisfying the following criteria in heterogeneity analysis:
(1) In copy neutral region (Log2ration between ( 0.1, 0.1) in CNV analysis).
(2) Not in regions with LOH (LOH value o0.1).
(3) With MAF 40.05 or mutant allele count 42.
We drew the kernel density estimate plot for MAFs of the qualifying SNVs
using the density function in the stat package in R. We also estimated the number
of signiﬁcant peaks and the relative MAF component for each peak (peaks with less
than ﬁve SNVs, peaks with less than 1% SNVs and peaks with excessive variance
were ignored). A sample with heterogeneity shows density peaks at a MAF smaller
than 0.5 (the expected MAF assuming heterogeneous SNVs).
Kataegis analysis. Kataegis analysis was performed on all validated Tier1–3 SNVs
and SV breakpoints for each sample. The intermutation distance for a SNV was
calculated as the distance to its nearest neighbour. For each SNV, its distance to the
nearest validated SV breakpoint was also calculated. We deﬁned microclusters of
kataegis as clusters that contain at least ﬁve consecutive SNVs with intervariant
distance less than 10 kb. Mutant allele frequency (MAF) was estimated for SNVs
with at least 20 coverage in tumour BAMs based on deep sequencing of custom
capture validation.
Whole-genome sequencing. WGS was performed as previously described42,43.
WGS mapping, coverage, quality assessment, SNV, indel detection, tier annotation
for SNVs, prediction of deleterious effects of missense mutations and identiﬁcation
of LOH have been described previously42. SVs were analysed by using the CREST
software and were being annotated as previously described42,44. The reference
human genome assembly NCBI Build 37 was used for mapping samples. CNAs
were identiﬁed by comparing read depth in tumour versus matched normal
samples and using a novel algorithm, CONSERTING (COpy Number
SEgmentation by Regression Tree In Next-Gen sequencing).
SNVs were classiﬁed according to the following three tiers, as previously
described42.
Tier1: Coding synonymous, nonsynonymous and splice-site variants and
noncoding RNA variants.
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Tier 2: Conserved variants (cutoff conservation scoreZ500, based on either the
phastConsElements28way table or the phastConsElements17way table from the
UCSC genome browser (http://genome.ucsc.edu/) and variants in regulatory
regions annotated by UCSC annotation (regulatory annotations included
targetScanS, ORegAnno, tfbsConsSites, vistaEnhancers,eponine, ﬁrstEF, L1 TAF1
Valid, Poly(A), switchDbTss, encodeUViennaRnaz, laminB1 and cpgIslandExt)).
Tier 3: Variants in nonrepeat masked regions.
Tier 4: All other SNVs.
Exome sequencing. For exome sequencing, DNA libraries were prepared from
1 mg of WGA DNA from matched samples by using the Illumina TruSeq DNA
library prep kit according to the manufacturer’s protocol. The quality of library
construction was assessed on an Agilent Bioanalyzer. Germline and diagnostic
library samples were independently pooled for exome capture by using the Illu-
mina TruSeq Exome Enrichment kit as instructed by the manufacturer. Captured
libraries were then clustered on the Illumina c-bot and sequenced on an Illumina
HiSeq 2000 platform by conducting 100 base pair-end-multiplexed reads at an
equivalent of three samples per lane.
Sequence validation. To enrich regions containing putative sequence alterations,
genomic coordinates of the WGS targets were used to order Nimbelgen Seqcap EZ
solution bait sets (Roche). Library construction and target enrichment were per-
formed as per the manufacturer’s instructions, using repli-G (Qiagen) WGA DNA.
Enriched targets were sequenced on the Illumina platform by paired-end 100-cycle
sequencing. The resulting data were converted to FASTQ ﬁles by using the
CASAVA 1.8.2 (Illumina) programme and were mapped with a Burrows-Wheeler
Aligner before pipeline analysis. Putative SNVs and indels from exon sequencing
were validated by next-generation amplicon sequencing. Brieﬂy, primers were
designed for genomic regions (hg19) ﬂanking the detected SNV but no nearer than
100 base pairs. PCR was performed by using 20–30 ng of WGA DNA from each
sample. DNA from diagnostic tumour samples and matched germline samples was
used for each primer set to conﬁrm the presence of the SNV/indel in the diagnostic
sample. Standard PCR was performed in 25-ml reactions, using Accuprime GC-rich
DNA polymerase (Invitrogen) with the following reaction conditions: 95 C for
3min; 35 cycles of 95 C for 30 s, 65 C for 30 s and 72 C for 1min; and a 72 C for
10min extension with cooling to 4 C. All PCR amplicons were veriﬁed on a 2%
E-gel (Invitrogen) to ensure single ampliﬁed product.
Transcriptome sequencing. For library construction, 2–5mg of total RNA was
extracted from tumour samples by using Qiagen RNeasy Mini kits according to the
manufacturer’s instructions. RNA concentration was measured by using a Nano-
Drop 100 Spectrophotometer (Thermo Scientiﬁc). RNA integrity was measured by
using an Agilent Technologies 2100 Bioanalyzer Lab-on-a-chip system. Total RNA
was treated with DNAse I (Invitrogen) and enriched for poly A-containing mRNA
using oligo dT beads (Dynabeads, Invitrogen). The cDNA synthesis used random
hexamers and the Superscript Double-Stranded cDNA Synthesis kit (Invitrogen).
Paired-end reads from mRNA-seq were aligned to the following four database ﬁles
by using a Burrows-Wheeler Aligner (0.5.5; (ref. 45: (i) human NCBI Build 37
reference sequence, (ii) RefSeq, (iii) a sequence ﬁle representing all possible
combinations of nonsequential pairs in RefSeq exons and (iv) AceView database
ﬂat ﬁle downloaded from UCSC, representing transcripts constructed from human
expressed sequence tag (EST). The mapping results from databases (ii)–(iv) were
aligned to human reference genome coordinates. The ﬁnal BAM ﬁle (compressed
binary version of the Sequence Alignment/Map format) ﬁle was constructed by
selecting the best alignment in the four databases. The RNA expression level was
measured by fragments per kilobase of transcript per million fragments mapped46.
SVs were detected by using the CIRCERO algorithm, a novel algorithm that uses de
novo assembly to identify SV in RNA-seq data (unpublished data). The structural
variants detected in RNA-seq data were validated with MiSeq sequencing. Primer
pairs were designed (with Primer3) to bracket the genomic regions containing
putative SVs. The SVs found by RNA-seq are reported in Supplementary Table 4.
GISTIC analysis. We used cghMCR (an R implementation of a modiﬁed version
of the GISTIC analysis47) to ﬁnd regions that contained copy number alterations.
We identiﬁed signiﬁcantly ampliﬁed genes as those with segments of gain or loss
(SGOL) scores 3 s.d.’s above the mean SGOL scores of all ‘gains’. Genes with SGOL
scores 3 s.d.’s below the mean SGOL scores of all ‘losses’ were selected as
signiﬁcantly deleted genes.
Timing of cn-LOH. The cn-LOH regions were estimated from the CNA and LOH
analysis data. When cn-LOH was identiﬁed in a pure tumour cell population,
heterozygous alleles had become homozygous for either the reference allele or the
alternative allele. Consequently, the MAF for SNVs accumulating before cn-LOH
was either 0 (homozygous reference allele) or 1 (homozygous alternative allele),
while SNVs occurring after cn-LOH had a maximum MAF of 0.5 (assuming no
second mutation at the same locus) in tumour cells. We inferred the temporal
order of cn-LOH and SNV accumulation in a genomic segment by comparing the
AI values with the region’s MAF.
Telomeric DNA content and telomere FISH. The WGS data were analysed for
total telomeric DNA content in tumours and matched germline DNA in 19 cases.
Telomeric content reads containing (TTAGGG)4 or (CCCTAA)4 were counted
and normalized to the average genomic coverage, and the log2 ratio of diagnostic
and germline telomeric content estimates was then calculated to allow classiﬁcation
of telomeric content as gain, no change or loss48. Telomere FISH was performed on
available formalin-ﬁxed, parafﬁn-embedded tissue samples (n¼ 22) from the WGS
and WES cohorts. Interphase FISH was performed on 4-mm-thick, formalin-ﬁxed,
parafﬁn-embedded tissue sections. The Cy3-labelled TelG probe (PNAbio) was co-
denatured with the target cells on a hotplate at 90 C for 12min. The slides were
incubated for 48 h at 37 C and then washed in 4M urea/2 SSC at 45 C for
5min. Nuclei were counterstained with 200 ngml 1 of 40 ,6-diamidino-2-
phenylindole (Vector Laboratories). The telomeric probe (red) hybridizes to
telomeres on all chromosomes; a probe for 4p (green) was used as control.
Analysis of microsatellite markers on chromosome 11p. To identify commonly
deleted regions on chromosome 11p15, we assessed LOH in 16 paired normal and
tumour DNAs selected from the recurrence groups (WES) and in 22 additional
IPACTR cases. We included peripheral blood DNA from 23 pairs of parents.
Genomic DNA was extracted by using standard protocols. Fluorescence PCR semi-
automated genotyping was used to detect and analyse allelic losses by using a panel
of ﬁve microsatellite markers (D11S1363, D11S922, D11S4046, HUMTH01 and
D11S988).
TP53 and CTNNB1 mutations. To detect and validate TP53 and CTNNB1
mutations, genomic DNA from ACT samples was tested by PCR-based bidirec-
tional DNA sequencing of exons 2–11 and intron–exon boundaries for TP53 and
exon 3 (codons 5–70) for CTNNB1. Sequencing reactions were carried out on a
high-throughput 3730xl DNA Analyzer (Applied Biosystems).
TERT core promoter mutational status. The TERT core promoter (HG19
coordinates, chr5: 1295151–1295347) was ampliﬁed in 19 paediatric ACT using
PCR. Brieﬂy, 10–20 ng of sample DNA was added to a 25-ml reaction containing
amplitaq gold 360 master mix (Applied Biosystems) with 400 nM each of ampli-
ﬁcation primers (50-CAGCGCTGCCTGAAACTCG-30 (sense) and 50-CCACGT
GGCGGAGGGACT-30 (antisense)) resulting in a PCR product of 197 bp.
Sequencing reactions were carried out on a high-throughput 3730xl DNA Analyzer
(Applied Biosystems).
HHV6 chromosomal integration. We ampliﬁed the sequences of the HHV6
major capsid protein and U94 genes in tumour and blood DNA from cases in the
WGS and WES cohorts (n¼ 37). PCR and cycling conditions followed a previously
described protocol49,50. Cases positive by PCR were tested using the FISH analysis.
Peripheral blood mononuclear cells were cultured for 72 h in RPMI 1640
containing 20% FCS and 10 mgml 1 phytohemagglutinin (PHA). After 1.0 h of
colcemide treatment, cells were harvested according to the standard cytogenetic
techniques. Cells in the metaphase were examined with FISH using HHV6 cosmid
probes labelled by nick translation with ﬂuorescein-dUTP and a dual-colour probe
mapped to the sequences 50 and 30 of the common breakpoint region within the
MLL locus (11q23; Abbott Molecular). The HHV6/MLL probe mixture was applied
to target metaphases and incubated at 37 C overnight. After the slide was washed
with 2 SSC, 10ml of 4,6-diamidino-2-phenylindole counterstain was applied to
the target area for visualization.
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